More aggressive targets for blood pressure can significantly reduce cardiovascular disease and death

14 September 2015
nih-big

Aggressive targeting for lowering blood pressure significantly reduced rates of cardiovascular disease and death, according to new study data.

The SPRINT study, sponsored primarily by the US National Heart, Lung, and Blood Institute (NHLBI), was conducted by the US National Institutes of Health and involved more than 9,000 participants aged 50 years and above, who had hypertension at higher risk for heart disease or who had kidney disease.

The patients were randomized to a standard treatment group, receiving on average two different hypertension drugs to achieve the currently-recommended systolic blood pressure target of less than 140mm Hg, or to a group receiving intense therapy, which was given an average of three medications to attain less than 120mm HG. The study excluded patients with diabetes, a prior stroke or polycystic kidney disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical